BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klok, A.-M.
Right arrow Articles by Kijlstra, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klok, A.-M.
Right arrow Articles by Kijlstra, A.
Br J Ophthalmol 1999;83:847-851 ( July )

Soluble ICAM-1 serum levels in patients with intermediate uveitis

Anne-Marie Kloka b c, Leny Luyendijka, Michel J W Zaalb, Aniki Rothovad, Aize Kijlstraa c

a Department Ophthalmo-Immunology, Netherlands Ophthalmic Research Institute, Amsterdam, b Department of Ophthalmology, Free University, Amsterdam, c Department of Ophthalmology, University of Amsterdam, Amsterdam, d Department of Ophthalmology, University of Utrecht, Utrecht

Correspondence to: Anne-Marie Klok, Department Ophthalmo-Immunology, Netherlands Ophthalmic Research Institute, Amsterdam, PO Box 12141, 1100 AC Amsterdam, Netherlands.

Accepted for publication 12 January 1999

AIM---To investigate whether serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) can serve as a marker of the presence of systemic disease in intermediate uveitis.
METHODS---In a multicentre study sICAM-1 serum levels were measured in 61 patients with idiopathic intermediate uveitis, controls included 56 uveitis patients with a systemic disease (26 sarcoid associated uveitis and 30 HLA-B27 positive acute anterior uveitis), 58 uveitis patients without systemic disease (30 toxoplasma chorioretinitis and 28 Fuchs' hetrochromic cyclitis), and 21 normal controls. The clinical records of the patients with intermediate uveitis were analysed for disease characteristics at the time of blood sampling and for a relation with the development of a systemic disease after a mean follow up of 4.5 years.
RESULTS---Increased serum levels of sICAM-1 were found in 34 out of 61 patients with intermediate uveitis and were significantly different when compared with toxoplasmosis, Fuchs' cyclitis, and healthy controls (p<0.001). Elevated sICAM-1 levels were also found in 18 out of 26 patients with sarcoid uveitis and in 11 out of 30 patients with HLA-B27 associated anterior uveitis. Raised sICAM-1 levels in the intermediate uveitis group were significantly associated with active ocular disease (p<0.01) and the presence of vitreous exudates (p<0.05). Increased levels of sICAM-1 correlated with interleukin 8 levels (IL-8) (tested in a previous study in the same group of intermediate uveitis patients) in patients with active systemic involvement. Follow up of the patients showed that an established or suspected systemic disease was found more often in the 21 intermediate uveitis patients with increased sICAM-1 and IL-8 levels compared with the other 40 patients with intermediate uveitis (p<0.01).
CONCLUSIONS---The measurement of both sICAM-1 and IL-8 can be used as a marker for ocular disease activity and for a predisposition of developing an associated systemic disease in intermediate uveitis patients.


© 1999 by British Journal of Ophthalmology



This article has been cited by other articles:


Home page
Br. J. Ophthalmol.Home page
C C Murphy, L Duncan, J V Forrester, and A D Dick
Systemic CD4+ T cell phenotype and activation status in intermediate uveitis
Br. J. Ophthalmol., March 1, 2004; 88(3): 412 - 416.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1999 by the BMJ Publishing Group Ltd.